SCHEMBL6918600

SCHEMBL6918600

CCCCOc1c(O)nc(C(C)(C)C)nc1O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.37
NR5A1 Q13285 1/20 0.37
CYP2D6 P10635 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP19A1 P11511 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
THRA P10827 1/20 0.34
THRB P10828 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
TP53 P04637 1/20 0.33
TSHR P16473 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
HPGD P15428 1/20 0.33
RAB9A P51151 1/20 0.33
PLA2G4B P0C869 2/20 0.33
TLR4 O00206 1/20 0.33
ESR1 P03372 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6918499 0.79 SMN1; SMN2 (0.36) LTA4HCYP2D6CYP1A2CYP19A1CYP2C9
SCHEMBL6919616 0.75 LTA4H (0.42) LTA4HNR5A1CYP2D6CYP1A2CYP19A1
SCHEMBL5587446 0.72 LTA4H (0.40) LTA4HNR5A1CYP2D6CYP1A2CYP19A1
SCHEMBL10692851 0.68 LTA4H (0.46) LTA4HNR5A1CYP2D6CYP1A2CYP19A1
SCHEMBL12646952 0.66 ALDH1A1 (0.46) LTA4HNR5A1SMN1; SMN2TSHRGSTA1
SCHEMBL14718249 0.65 SCN2A (0.45) LTA4HNR5A1SMN1; SMN2ESR1
SCHEMBL5586804 0.65 LTA4H (0.44) LTA4HNR5A1CYP2D6CYP1A2CYP19A1
SCHEMBL15187966 0.64 THRA (0.42) THRATHRBLMNAPOLBTLR4
SCHEMBL17585442 0.64 LTA4H (0.40) LTA4HNR5A1CYP2D6SMN1; SMN2TP53
SCHEMBL27934690 0.64 ALDH1A1 (0.46) LTA4HCYP2D6CYP1A2CYP19A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462123-B1 4,5,6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2013-10-02 EP disclosed
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2012-05-31 US disclosed
WO-2011017296-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS SCHERING CORPORATION (US) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS F9, F8, F12 LTA4H 770/4885NR5A1 1336/4885CYP2D6 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.